UCB Transplant After Non-Myeloablative Prep for Blood Cancers
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen with modifications based on factors including diagnosis, disease status, and prior treatment. Single or double unit selected according to current University of Minnesota umbilical cord blood graft selection algorithm.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
How is the UCB transplant treatment with Cyclophosphamide, Fludarabine, and TBI different from other treatments for blood cancers?
What data supports the effectiveness of the drug Cyclophosphamide in the treatment of blood cancers?
The research articles provided focus on the use of Cyclophosphamide in treating systemic lupus erythematosus (SLE), not blood cancers. However, Cyclophosphamide is a well-known chemotherapy drug often used in various cancer treatments, including blood cancers, due to its ability to kill rapidly dividing cells.678910
Who Is on the Research Team?
Margaret MacMillan, MD
Principal Investigator
University of Minnesota
Are You a Good Fit for This Trial?
This trial is for people under 75 with certain blood cancers or bone marrow diseases who don't have a fully matched sibling donor. They must be in good enough health, agree to birth control if they can have children, and give written consent. It's not for pregnant women, those breastfeeding, or patients with specific progressing lymphomas or recent transplants.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Preparative Regimen
Participants receive a non-myeloablative preparative regimen including cyclophosphamide, fludarabine, and total body irradiation (TBI) with modifications based on diagnosis, disease status, and prior treatment
Transplantation
Umbilical cord blood transplantation is performed using single or double unit selected according to the University of Minnesota umbilical cord blood graft selection algorithm
Follow-up
Participants are monitored for safety and effectiveness, including assessment of acute GVHD and chimerism
What Are the Treatments Tested in This Trial?
Interventions
- Cyclophosphamide
- Fludarabine
- Sirolimus
- TBI
Cyclophosphamide is already approved in United States, European Union, Canada, Japan for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Masonic Cancer Center, University of Minnesota
Lead Sponsor